SCHEMBL6355682

SCHEMBL6355682

CCOC(=O)c1cc2c(NCc3ccc(Cl)c(Cl)c3)cccc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.48
TSHR P16473 3/20 0.48
CD38 P28907 1/20 0.45
ALOX15 P16050 1/20 0.44
CNR1 P21554 1/20 0.43
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
PTGES O14684 1/20 0.43
ALOX5 P09917 1/20 0.43
RAB9A P51151 3/20 0.42
MEN1 O00255 2/20 0.42
NPC1 O15118 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
LMNA P02545 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6358545 0.86 SMN1; SMN2 (0.49) SMN1; SMN2ALOX15ALOX5RAB9AMEN1
SCHEMBL4044123 0.78 CDK1 (0.57) SMN1; SMN2ALOX15CDK1CCNB1ALOX5
SCHEMBL28659544 0.76 MMP13 (0.57) SMN1; SMN2TSHRALOX15RAB9AMEN1
SCHEMBL28677621 0.74 MMP13 (0.59) SMN1; SMN2TSHRALOX15RAB9AMEN1
SCHEMBL29865229 0.74 IDO1 (0.58) ALOX15CNR1CDK1CCNB1PTGES
SCHEMBL28844597 0.74 IDO1 (0.58) ALOX15CNR1CDK1CCNB1PTGES
SCHEMBL30525427 0.73 ALOX15 (0.57) SMN1; SMN2ALOX15CDK1CCNB1ALOX5
SCHEMBL699665 0.73 ALOX15 (0.57) SMN1; SMN2ALOX15CDK1CCNB1ALOX5
SCHEMBL7954222 0.73 ALOX15 (0.57) SMN1; SMN2ALOX15CDK1CCNB1ALOX5
SCHEMBL701020 0.73 KDM4E (0.57) SMN1; SMN2ALOX15CDK1CCNB1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911465-B1 Anti-inflammatory indole derivatives ASTRAZENECA AB (SE) 2005-06-28 US disclosed
US-20050026975-A1 Anti-inflammatory indole derivatives ASTRAZENECA AB (SE) 2005-02-03 US disclosed
EP-1150954-B1 ANTI-IMFLAMMATORY INDOLE DERIVATIVES ASTRAZENECA AB (SE) 2004-10-13 EP disclosed
US-6569888-B1 Such as ethyl-N-(dichlorobenzyl)-4-(3-hydroxypropylthio) indole-2-carboxylate; for treatment of arthritis ASTRAZENECA AB (SE) 2003-05-27 US disclosed
EP-1159269-B1 ANTI-IMFLAMMATORY INDOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-03-26 EP disclosed
EP-1159269-A1 ANTI-IMFLAMMATORY INDOLE DERIVATIVES AstraZeneca AB (SE) 2001-12-05 EP disclosed
EP-1150954-A1 ANTI-IMFLAMMATORY INDOLE DERIVATIVES AstraZeneca AB (SE) 2001-11-07 EP disclosed
WO-2000046198-A1 ANTI-INFLAMMATORY INDOLE DERIVATIVES ASTRAZENECA AB (SE) 2000-08-10 WO disclosed
WO-2000046195-A1 ANTI-INFLAMMATORY INDOLE DERIVATIVES ASTRAZENECA AB (SE) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026975-A1 Anti-inflammatory indole derivatives CCR5, CCR2, CCL5 SMN1; SMN2 3741/4885TSHR 535/4885CD38 2929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.